Page 647 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

CHAPTER 28 Tumors of the Mammary Gland 625

200. Perez-Alenza MD, Jimenez A, Nieto AI, et al.: First description of 214. Kamstock DA, Fredrickson R, Ehrhart EJ: Lipid-rich carcinoma of
feline inflammatory mammary carcinoma: clinicopathological and the mammary gland in a cat, Vet Pathol 42:360–362, 2005.
immunohistochemical characteristics of three cases, Breast Cancer 215. Matsuda K, Kobayashi S, Yamashita M, et al.: Tubulopapillary car-
VetBooks.ir 201. McNeill CJ, Sorenmo KU, Shofer FS, et al.: Evaluation of adjuvant cinoma with spindle cell metaplasia of the mammary gland in a cat,
Res 6:R300–307, 2004.
J Vet Med Sci 70:479–481, 2008.
doxorubicin-based chemotherapy for the treatment of feline mam-
mary carcinoma, J Vet Intern Med 23:123–129, 2009. 216. Zappulli V, Caliari D, Rasotto R, et al.: Proposed classification of
the feline “complex” mammary tumors as ductal and intraductal
202. Goldschmidt MH, Pena L, Zappulli V: Tumors of the mammary papillary mammary tumors, Vet Pathol 50:1070–1077, 2013.
gland. In Meuten DJ, editor: Tumors in domestic animals, ed 5, 217. Seixas F, Palmeira C, Pires MA, et al.: Grade is an independent
Oxford, UK, 2017, John Wiley and Sons. prognostic factor for feline mammary carcinomas: a clinicopatho-
203. Soares M, Madeira S, Correia J, et al.: Molecular based subtyping logical and survival analysis, Vet J 187:65–71, 2011.
of feline mammary carcinomas and clinicopathological character- 218. Mills SW, Musil KM, Davies JL, et al.: Prognostic value of histo-
ization, Breast 27:44–51, 2016. logic grading for feline mammary carcinoma: a retrospective sur-
204. Soares M, Correia J, Peleteiro MC, et al.: St Gallen molecular sub- vival analysis, Vet Pathol 52:238–249, 2015.
types in feline mammary carcinoma and paired metastases-disease 219. MacEwen EG, Hayes AA, Harvey HJ, et al.: Prognostic factors for
progression and clinical implications from a 3-year follow-up study, feline mammary tumors, J Am Vet Med Assoc 185:201–204, 1984.
Tumour Biol 37:4053–4064, 2016. 220. MacEwen EG, Hayes AA, Mooney S, et al.: Evaluation of effect of
205. Caliari D, Zappulli V, Rasotto R, et al.: Triple-negative vimentin- levamisole on feline mammary cancer, J Biol Response Mod 3:541–
positive heterogeneous feline mammary carcinomas as a potential 546, 1984.
comparative model for breast cancer, BMC Vet Res 10(185), 2014. 221. Viste JR, Myers SL, Singh B, et al.: Feline mammary adenocarci-
206. Beha G, Muscatello LV, Brunetti B, et al.: Molecular phenotype of noma: tumor size as a prognostic indicator, Can Vet J 43:33–37,
primary mammary tumours and distant metastases in female dogs 2002.
and cats, J Comp Pathol 150:194–197, 2014. 222. Gemignani F, Mayhew PD, Giuffrida MA, et al.: Association of
207. Wiese DA, Thaiwong T, Yuzbasiyan-Gurkan V, et al.: Feline mam- surgical approach with complication rate, progression-free sur-
mary basal-like adenocarcinomas: a potential model for human tri- vival time, and disease-specific survival time in cats with mam-
ple-negative breast cancer (TNBC) with basal-like subtype, BMC mary adenocarcinoma: 107 cases (1991–2014), J Am Vet Med Assoc
Cancer 13:403, 2013. 252:1393–1402, 2018.
208. Brunetti B, Asproni P, Beha G, et al.: Molecular phenotype in 223. Borrego JF, Cartagena JC, Engel J: Treatment of feline mammary
mammary tumours of queens: correlation between primary tumour tumours using chemotherapy, surgery and a COX-2 inhibitor drug
and lymph node metastasis, J Comp Pathol 148:206–213, 2013. (meloxicam): a retrospective study of 23 cases (2002–2007), Vet
209. Hayden DW, Barnes DM, Johnson KH: Morphologic changes Comp Oncol 7:213–221, 2009.
in the mammary gland of megestrol acetate-treated and untreated 224. Jeglum KA, deGuzman E, Young KM: Chemotherapy of advanced
cats: a retrospective study, Vet Pathol 26:104–113, 1989. mammary adenocarcinoma in 14 cats, J Am Vet Med Assoc 187:157–
210. Castagnaro M, Casalone C, Bozzetta E, et al.: Tumour grading and 160, 1985.
the one-year post-surgical prognosis in feline mammary carcino- 225. Mauldin GN, Matus RE, Patnaik AK, et al.: Efficacy and toxic-
mas, J Comp Pathol 119:263–275, 1998. ity of doxorubicin and cyclophosphamide used in the treatment
211. Seixas F, Palmeira C, Pires MA, et al.: Mammary invasive micro- of selected malignant tumors in 23 cats, J Vet Intern Med 2:60–65,
papillary carcinoma in cats: clinicopathologic features and nuclear 1988.
DNA content, Vet Pathol 44:842–848, 2007. 226. Karayannopoulou M, Kaldrymidou E, Constantinidis TC, et al.:
212. Seixas F, Pires MA, Lopes CA: Complex carcinomas of the mam- Adjuvant post-operative chemotherapy in bitches with mammary
mary gland in cats: pathological and immunohistochemical fea- cancer, J Vet Med A Physiol Pathol Clin Med 48:85–96, 2001.
tures, Vet J 176:210–215, 2008. 227. Hahn K, Richardson R, Knapp D: Canine malignant mammary
213. Sarli G, Brunetti B, Benazzi C: Mammary mucinous carcinoma in neoplasia: biological behavior, diagnosis, and treatment alterna-
the cat, Vet Pathol 43:667–673, 2006. tives, J Am Anim Hosp Assoc 28:251–256, 1992.